

Appl. No. : 09/632,074  
Filed : August 2, 2000

60% similarity thereto while retaining leptin activity or antagonist activity as well as a molecule encoded by the nucleotide sequence set forth in (SEQ ID NO:1) or a nucleotide sequence having at least about 60% similarity thereto or a nucleotide sequence capable of hybridising to (SEQ ID NO:1) under low stringency conditions at 42°C.

On page 19, please remove Table 4 and replace it with the following Table 4: --

Gene	Forward Primer	Backward Primer	Product Size
GAPDH	5=CAGTCAGCCGCATCTTCTTTTG 3= (SEQ ID NO:3)	5=TGGTTCACACCCATGACGAAC 3= (SEQ ID NO:4)	464bp
OPG	5=GTACGTCAAGCAGGAGTGCAATC 3= (SEQ ID NO:5)	5=TTCTTGTGAGCTGTGTTGCCG 3= (SEQ ID NO:6)	472 bp
RANK	5=TTAAGCCAGTGCTTCACGGG 3= (SEQ ID NO:7)	5=ACGTAGACCACGATGATGTCGC 3= (SEQ ID NO:8)	497 bp

**IN THE SEQUENCE LISTING:**

Please cancel the original sequence listing, pages i-vi and insert the attached Replacement Sequence Listing pages 1-4.

**REMARKS**

The amendments made herein conform the application to practice in the United States Patent and Trademark Office. This response to Notice to Comply conforms the sequence listing to the rules of practice specified by the U.S. Patent and Trademark Office. Enclosed herewith are (1) a paper copy of the Replacement Sequence Listing, and (2) a computer readable copy of the Replacement Sequence Listing.

The changes made to the claims by the current amendment, including **[deletions]** and **additions**, are shown on an attached sheet entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment.

**VERIFICATION UNDER 37 C.F.R. §1.821(f) & (g)**

The polypeptide sequence appearing in the attached Sequence Listing was included in the application as filed. Pursuant to 37 C.F.R. §1.821(g), no new matter is being added herewith. As required under 37 C.F.R. §1.821(f), I hereby verify that the data on the enclosed disk and the paper copies of the Sequence Listing are identical.

Appl. No. : 9/632,074  
Filed : August 2, 2000

CONCLUSION

Applicants believe this Response to Notice to Comply brings the present application into compliance with the Sequence Listing requirements. Entry and examination on the merits are respectfully requested.


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12-20-01

By:



Jennifer A. Haynes, Ph.D.  
Registration No. 48,868  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

H:\DOCS\JAH\JAH-4630.DOC  
071001

Appl. No. : 9/632,074  
Filed : August 2, 2000

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

On page 1, second paragraph starting on line 16, please replace the paragraph with the following:

--Bibliographic details of the publications referred to by author in this specification are collected at the end of the description. Nucleotide and amino acid sequences are referred to by a sequence identifier, i.e. [~~400~~>1] (SEQ ID NO:1), [~~400~~>2] (SEQ ID NO:2), etc. A sequence listing is provided after the claims.--.

On page 7, third paragraph, starting on line 12, please replace the paragraph with the following paragraph: -- Reference herein to "leptin" includes reference to a polypeptide having the amino acid sequence set forth in [~~400~~>7] (SEQ ID NO:2) or an amino acid sequence having at least 60% similarity thereto while retaining leptin activity or antagonist activity as well as a molecule encoded by the nucleotide sequence set forth in [~~400~~>8] (SEQ ID NO:1) or a nucleotide sequence having at least about 60% similarity thereto or a nucleotide sequence capable of hybridising to [~~400~~>8] (SEQ ID NO:1) under low stringency conditions at 42°C.

On page 19, please remove Table 4 and replace it with the following Table 4: --

Gene	Forward Primer	Backward Primer	Product Size
GAPDH	5=CAGTCAGCCGCATCTTCTTTG 3= (SEQ ID NO:3)	5=TGGTTCACCCCATGACGAAC 3= (SEQ ID NO:4)	464bp
OPG	5=GTACGTCAAGCAGGAGTGCAATC 3= (SEQ ID NO:5)	5=TTCTTGTGAGCTGTGTGCCG 3= (SEQ ID NO:6)	472 bp
RANK	5=TTAAGCCAGTGCTTCACGGG 3= (SEQ ID NO:7)	5=ACGTAGACCACGATGATGTCGC 3= (SEQ ID NO:8)	497 bp